Chemistry:Namodenoson

From HandWiki
Short description: Chemical compound
Namodenoson
Namodenoson.svg
Clinical data
Other namesChloro-IB-MECA; 2-Cl-IB-MECA
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC18H18ClIN6O4
Molar mass544.73 g·mol−1
3D model (JSmol)

Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is developed by Can-Fite for non-alcoholic fatty liver disease,[1] liver cancer,[2] and pancreatic cancer.[3]

References

  1. Safadi, Rifaat; Braun, Marius; Francis, Adi; Milgrom, Yael; Massarwa, Muhammad; Hakimian, David; Hazou, Wadi; Issachar, Assaf et al. (December 2021). "Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis". Alimentary Pharmacology & Therapeutics 54 (11–12): 1405–1415. doi:10.1111/apt.16664. ISSN 1365-2036. PMID 34671996. 
  2. Stemmer, Salomon M.; Manojlovic, Nebojsa S.; Marinca, Mihai Vasile; Petrov, Petar; Cherciu, Nelly; Ganea, Doina; Ciuleanu, Tudor Eliade; Pusca, Ioana Adriana et al. (7 January 2021). "Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial". Cancers 13 (2): 187. doi:10.3390/cancers13020187. ISSN 2072-6694. PMID 33430312. 
  3. Fishman, Pnina; Bareket-Samish, Avital; Itzhak, Inbal (1 June 2023). "Effects of namodenoson on pancreatic carcinoma: Preclinical evidence.". Journal of Clinical Oncology 41 (16_suppl): e15134. doi:10.1200/JCO.2023.41.16_suppl.e15134.